Eupraxia Pharmaceuticals Inc's stock has seen notable fluctuations recently, reflecting investor sentiment amidst recent developments.
Eupraxia Pharmaceuticals Inc (EPRX.TO) has experienced a challenging week, with its stock price declining by 13.82% over the past week. As of the latest close, the stock is trading at C$10.30, down 2.01% on the day. This downturn follows a series of significant financial milestones and public offerings that have shaped the company's recent trajectory.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$592.68M
52W high
$12.86
52W low
$7.15
1W change
-13.82%
Beta
1.50
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 82.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.00
+82.0% Upside
Current Price
C$8.79
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
59.2%
Annualized
90-Day Vol
58.8%
Annualized
Trend (90d)
+22.6%
Annualized drift
90d Mean
C$9.53
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$9.03 | C$7.36 โ C$11.07 |
| 60 trading days | C$9.28 | C$6.95 โ C$12.38 |
| 90 trading days | C$9.53 | C$6.69 โ C$13.57 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain aware of Eupraxia's recent public offerings and financial results, which could influence market sentiment and stock performance moving forward.
C$10.30
Eupraxia Pharmaceuticals Inc's stock closed at C$10.30, reflecting a 2.01% decline today amidst a broader 13.82% drop this week.
Bull case
Eupraxia's recent public offerings, including a successful US$63.2 million raise, have strengthened its cash position. This financial boost could speed up clinical development and increase investor confidence.
Bear case
The company's stock has been volatile, facing challenges with its financial performance, including a negative profit margin and a decline in stock value this year. These factors may raise concerns for potential investors.
Recent Price Action
Advertisement
Eupraxia Pharmaceuticals Inc has faced a notable decline, with a current trading price of C$10.30, reflecting a 2.01% decrease on Wednesday. Over the past week, the stock has dropped by 13.82%, and year-to-date, it is down 15.97%. This volatility follows a period of substantial public offerings aimed at strengthening the company's financial position.
Company News and Catalysts
While there are no major news announcements directly impacting Eupraxia Pharmaceuticals this week, the company has been active in raising capital through public offerings. Notably, they closed a US$63.2 million public offering on February 20, 2026. Such capital raises are crucial for a clinical-stage biotechnology firm as they enable continued investment in research and development.
Technical Picture
From a technical standpoint, Eupraxia's stock is trading above its 50-day moving average of C$9.26, which is 11.2% higher than the current price. The 200-day moving average sits at C$9.88, indicating a 4.3% premium. The stock has a beta of 1.50, suggesting higher volatility compared to the broader market. The 52-week range for EPRX.TO has been C$7.15 to C$12.86, with the current price at approximately 55% of this range. Trading volume has also been noteworthy, with the latest volume at 127,774 shares, significantly above the 20-day average of 58,086 shares, indicating heightened trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
